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Summary
This article summarizes the contents of posters which were presented at the San Antonio Breast Cancer Symposium in sessions dealing with familial breast cancer, prevention, risk factors and genetics. Genetic testing for inherited or high-risk breast cancer was one of the main topics, focusing on the genetic counseling in women with hereditary breast cancer from different social and ethnic backgrounds. Information and training in breast self-awareness are important factors for reducing cancer anxiety. In mice, chemoprevention in breast cancer using retinoids showed to be effective by reducing tumor multiplicity. Vitamin A derivatives and COX 2 inhibitors could be potentially used to prevent breast cancer in woman at increased risk. Inhibition of EGFR (epidermal growth factor receptor) kinase reduces tumor multiplicity and could re-sensitize tumors to taxane chemotherapy. Analysis of histological subtypes of breast cancer demonstrated differences in DNA methylation and molecular marker expression. Lifestyle, e.g. oral contraception or hormone replacement therapy, is affecting patients at both basic and high risk of developing breast cancer.
Familial Breast Cancer, Prevention, Risk Factors and Genetics -Highlights from the San Antonio Breast Cancer Symposium (SABCS) Poster Presentations Familial Breast Cancer
Genetic testing for hereditary breast cancer or in patients at high risk of developing breast cancer was a topic that was approached from different angles at this San Antonio Breast Cancer Symposium (SABCS). In Germany, genetic counseling and testing is available in 12 university centers. An interdisciplinary team of geneticists, gynecologists and psychologists is involved in the counseling process and is providing expert opinions on intensified surveillance programs and breast cancer prevention (e.g. chemoprevention or prophylactic surgery) [1] . Since the summer of 2005, the genetic counseling program composed of genetic testing, interdisciplinary counseling and clinical prevention program is included in the benefits of many German health insurance companies. The service is utilized by referral or is directly approached by motivated and informed women. The counseling is organized differently in other countries. One special focus of the SABCS was on the access to such programs by underserved women [2] -often lacking health insurance coverage -or women of different ethnic backgrounds [3] . Women were more often actively recruited for such programs, since a lack of information often is a reason for not participating. Recruiting patients actively did not cause any additional short-term psychological burden [4] . Among underserved women in the US, the offered genetic counseling was well accepted. In a small cohort of such women, Reyes et al. [5] reported more BRCA 2 mutations. With respect to family history, this cohort was not very well characterized. However, despite the limited number of patients in this study; ethnic background might be a factor worth considering in genetic counseling. Mutations in the CHEK2 gene (CHEK2*1000delC) were not significantly different when a population-based cohort (0.9%) was compared to a clinic-based breast cancer cohort (0.8%). However, within the subgroup of patients with early-onset breast cancer this mutation was found at a frequency of 2.3% referring to an increased breast cancer risk of 2.6. In patients with familial breast cancer tested negative for BRCA1 and BRCA2 mutations, CHEK2*1000delC mutations were found at a frequency of 1.4%, constituting an increased breast cancer risk of 1.5 [6] . The CHEK2 gene is of low penetrance and does not seem to play a pivotal role in hereditary breast cancer [7] .
Prevention
Prevention is still one of the pitfalls in breast cancer therapy. So far, no surrogate marker (i.e. serum marker) has been established for routine use. Even in high-risk breast cancer families genetic testing cannot provide definite certainty. Therefore, different prevention strategies should be offered to patients of normal or high breast cancer risk: i) breast selfawareness programs, ii) mammography screening programs, iii) chemoprevention and iv) prophylactic operations, such as prophylactic skin sparing mastectomy or bilateral salpingooophorectomy (BSO). By introducing breast self-examination courses and general information, the level of breast cancer worries and anxiety as one of the reasons for turning down screening offers could be reduced [8] . Offering invasive prophylactic procedures must be based on acceptance levels. More than 70% of patients (mutation carriers or high-risk family history) decided to take part in intensified surveillance programs rather than in preventive surgery [2, 9] . Intensified surveillance programs are also available for patients counseled within the German working group of 'Konsortium familiärer Brust-und Eierstockkrebs'. This program includes breast examination, ultrasound (biannually), mammography and magnetic resonance imaging (annually). It is mandatory that all examinations are conducted in one of the specialized centers to warrant continuous and standardized follow-up examinations. Surgical prevention strategies reduce the risk by > 98% in the case of prophylactic mastectomy [10, 11] . BSO reduced the breast cancer risk by 50% when performed before the age of 40 [12] [13] [14] . Despite this enormous risk reduction, the vast majority of patients at high risk of breast cancer did prefer the intensified breast cancer surveillance program. Prophylactic mastectomy was accepted by as few as 16% of the high-risk patients before the age of 35 [15] . Chemoprevention by anti-hormonal therapy outlines another strategy in breast cancer prevention. But since most of BRCA 1 mutation carriers develop non-hormone-sensitive breast cancer, this approach is under constant debate. The mean age of patients developing hereditary breast cancer is 20 years younger than with sporadic breast cancer. In this premenopausal setting, the selective estrogen receptor modulator tamoxifen is currently the only valid option. New approaches are combinations of low-dose tamoxifen (5 mg/day) and a vitamin A derivative, which have been shown to have a potential benefit [16] in premenopausal women at increased risk of breast cancer. However, the unusual tamoxifen dosage used might be one of the reasons that there was no synergistic effect. Preventing secondary breast cancer using the vitamin A analogue fenretinide showed a potential effect in premenopausal women [17] . One well recruiting ongoing study is the IBIS II study, in which postmenopausal women at moderate or high risk of breast cancer receive anastrozole or placebo. Patients with a histologically confirmed ductal carcinoma in situ (DCIS) receive tamoxifen 20 mg or anastrozole. Several poster presentations contained data relating to breast cancer prevention efficacy of different drugs in methylnitrosourea (MNU)-induced rat models. Retinoid X receptor (RXR)-specific retinoids decreased cancer multiplicity by up to 85% [18] . Similar results were demonstrated by Lubet et al. [19] regarding the RXR agonist targretin. Combinations of atorvastatin or lovastatins with RXR agonists or suboptimally dosed tamoxifen did not show a synergistic effect. Vitamin A analogues seemed to regulate cell cycle progression by inhibiting cyclin D1 and D3 [20] , differentiation and apoptosis [21, 22] . Nuclear retinoic receptors, such as the retinoid acid receptor (RAR) or RXR are ligand-activated transcription factors. Heterodimers of RAR and RXR bind to retinoic acid responsive elements (RARE) which in turn activate transcription factors [23] . Vitamin A derivatives might be of potential benefit but also have toxic side effects, such as hyperlipidemia, mucocutaneous toxicity and liver toxicity. The EGFR inhibitor gefitinib showed a marked reduction in tumor multiplicity by 88% [24] . Although the EGFR signaling pathway seemed to be a promising target in cancer therapy, gefitinib did not however show any advantage in treating nonsmall cell lunge cancer (FDA alert 6/2005). Inhibition of EGFR tyrosine kinase could reverse drug resistance by directly inhibiting phosphoglycolate phosphatase [25] . This could resensitize cancers to taxane therapy. It is tempting to introduce cyclooxygenase 2 inhibitors with known anti-angiogenic [26] , anti-proliferative and apoptotic [27] capacity into breast cancer prevention in women at increased risk. The investigation of surrogate markers for proliferation, such as the Ki-67 and ER expression level, in women at increased risk of breast cancer showed that celecoxib changed the level of ER expression significantly but did not have a significant influence on the Ki-67 level [28] . Inhibition of cyclooxygenase 2 reduced the aromatase activity in a dosedependent manner [29] . COX 2 levels were also downregulated by retinoids, such as LGD 1069, which also decreased levels of cyclin D1 in human mammary epithelial cells [30] .
Genetics
Although breast cancer is the most common malignancy in women in the Western world, the research community has not yet found a well accepted molecular surrogate marker for neither the detection of breast cancer nor the prediction of disease-free survival and overall survival. Genetic profiling is one of the approaches several groups have used to identify genetic fingerprints [31] . However, with these new techniques criticism is never far away, focusing on the fact that results are not consistently reproducible [32] . Another pitfall with genetic analysis is that findings at the transcriptional level do not always correlate with the protein level. But still, genetic analysis is one of the most powerful research tools. Comparing invasive lobular carcinoma and the high-grade pleomorphic variant did show that histomorphological differences were not always reflected by molecular characterization. Both entities seem to rely on genetic alteration on chromosomes 1q and 16q. Analyzed by comparative genomic hybridization, both variants had more gains than losses, and both were negative for E-cadherin [33] . The histological subtype of lobular breast cancer was also negative for p53 and HER-2 expression, but cyclin D1 was amplified promoting proliferation by regulating the cell cycle in the G1 phase [34, 35] . Polymorphism regarding this key regulator showed a difference in metastasis-free survival. A cyclin D1 870 G>A polymorphism was associated with a longer metastasis-free survival, although this polymorphism seems to correlate with hormone-insensitive breast cancers known to be clinically more aggressive [36] . Looking at different histological subtypes of breast cancer using the single nucleotide polymorphism (SNP) technique, the mean copy number in invasive ductal breast cancers was significantly different form invasive lobular breast cancers. By clustering tumors according to significantly different SNPs, a clear line of demarcation between the histological subtypes could be drawn. Within these clusters, SNPs located nearby genes encoding hormone response, cell adhesion or tumor suppression were identified. These results support the use of genetic analysis in differentiating tumor subtypes in order to find potential molecular targets [37] . DNA hypermethylation is a common step in carcinogenesis. It seems to occur in the early stages of breast cancer development. Hypermethylation of tumor suppressor genes, such as cyclin D 2 and RARβ2, were more frequent in DCIS than in invasive breast cancer [38] . BRCA1 methylation was correlated with fewer transcripts. Promoter hypermethylation occurred more frequently in younger women, high-grade and hormone receptor-negative tumors [39] .
Risk Factors
Lifestyle might be one factor that affects normal and high-risk groups equally. Hormonal treatment raises the question of increased breast cancer risk. Premenopausal women that used hormonal contraceptives prior to their breast cancer diagnosis do not have a worse prognosis. The fact that breast cancer is diagnosed earlier in patients using oral contraceptives is probably related to the more frequent visits to the doctor to get a prescription than to the effects of the pill. [40] . There is also an ongoing debate about the influence of hormone replacement therapy (HRT) on breast cancer risk [41, 42] . The Million Women Study [43] showed an increased risk of breast cancer in women using estrogen only. The risk was even more increased in women using a combination of estrogen and progesterone as HRT. Against the background of this study, investigations of molecular changes in breast tissue during HRT may give insights into the development of breast cancer. Using a pre-and post-treatment core biopsy of the breast after 6 months of combined estrogen-progestin HRT, no differences could be observed in the proliferation index assessed by Ki-67 staining. There was also no difference in the expression of estrogen or progesterone receptors, and HRT did not seem to have a positive influence on angiogenesis measured by CD 34 expression [44] . Further investigations are needed to find the molecular basis for increased breast cancer risk in women using HRT. 
